Research graph
References from Real-world efficacy, safety, and treatment continuity of fruquintinib in Japanese patients with colorectal cancer: a multicentre retrospective study. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Unresolved reference
2025 · External reference
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.003 · 2023 · External reference
A decade of progress: advances in the third-line treatment of patients with metastatic colorectal cancer
10.37765/ajmc.2024.89545 · 2024 · External reference
Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer
10.1056/nejmoa2214963 · 2023 · External reference
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
10.1056/nejmoa1414325 · 2015 · External reference
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
10.1016/s0140-6736(12)61900-x · 2013 · External reference
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
10.4161/15384047.2014.964087 · 2014 · External reference
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
10.1016/s0140-6736(23)00772-9 · 2023 · External reference
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan
10.1007/s10147-025-02852-9 · 2025 · External reference
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
10.1007/s10637-014-0154-x · 2015 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Unresolved reference
2025 · External reference
Investigation of the freely available easy-to-use software “EZR” for medical statistics
10.1038/bmt.2012.244 · 2013 · External reference
Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials
10.1016/j.ejca.2015.05.017 · 2015 · External reference
Treatment of metastatic colorectal cancer: ASCO guideline
10.1200/jco.22.01690 · 2023 · External reference
Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology
2024 · External reference
Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese society for cancer of the colon and rectum multicenter observational study
10.1634/theoncologist.2017-0275 · 2018 · External reference
Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial
10.1001/jama.2018.7855 · 2018 · External reference
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data
10.1038/bjc.2016.147 · 2016 · External reference
An observational/translational study to conduct real-world evidence and develop biomarkers of fruquintinib for patients with metastatic colorectal cancer (mCRC): FruBLOOM trial (JACCRO CC-19)
2025 · External reference
